Patrik Jeanmonod Cytek Biosciences, Inc. (CTKB) insider trading activity

Patrik Jeanmonod is CHIEF FINANCIAL OFFICER of Cytek Biosciences, Inc.. Currently has a direct ownership of 97,465 shares of CTKB, which is worth approximately $638,395. The most recent transaction as insider was on Mar 11, 2024, when has been sold 1,912 shares (Common Stock) at a price of $7.22 per share, resulting in proceeds of $13,804. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 97.5K

0% 3M change

4.35% 12M change

Total Value Held $638,395

Patrik Jeanmonod Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 11 2024	SELL Payment of exercise price or tax liability	$13,804 $7.22 p/Share	1,912 Reduced 1.92%	97,465 Common Stock
Mar 11 2024	BUY Exercise of conversion of derivative security	-	4,908 Added 4.71%	99,377 Common Stock
Feb 20 2024	SELL Payment of exercise price or tax liability	$5,723 $8.38 p/Share	683 Reduced 0.72%	94,469 Common Stock
Feb 20 2024	BUY Exercise of conversion of derivative security	-	1,752 Added 1.81%	95,152 Common Stock
Dec 26 2023	SELL Open market or private sale	$28,500 $9.5 p/Share	3,000 Reduced 3.11%	93,400 Common Stock
Nov 24 2023	SELL Open market or private sale	$20,820 $6.94 p/Share	3,000 Reduced 3.02%	96,400 Common Stock
Nov 18 2023	SELL Payment of exercise price or tax liability	$12,659 $5.98 p/Share	2,117 Reduced 2.09%	99,400 Common Stock
Nov 18 2023	BUY Exercise of conversion of derivative security	-	5,433 Added 5.11%	100,834 Common Stock
Oct 24 2023	SELL Open market or private sale	$14,040 $4.68 p/Share	3,000 Reduced 3.03%	96,084 Common Stock
Sep 25 2023	SELL Open market or private sale	$19,140 $6.38 p/Share	3,000 Reduced 2.94%	99,084 Common Stock
Aug 24 2023	SELL Open market or private sale	$23,070 $7.69 p/Share	3,000 Reduced 2.85%	102,084 Common Stock
Aug 18 2023	SELL Payment of exercise price or tax liability	$17,909 $8.46 p/Share	2,117 Reduced 1.97%	105,084 Common Stock
Aug 18 2023	BUY Exercise of conversion of derivative security	-	5,433 Added 4.85%	106,518 Common Stock
Jul 24 2023	BUY Open market or private sale	$27,510 $9.17 p/Share	3,000 Added 2.86%	101,768 Common Stock
Jun 26 2023	SELL Open market or private sale	$23,880 $7.96 p/Share	3,000 Reduced 2.78%	104,768 Common Stock
May 24 2023	SELL Open market or private sale	$23,280 $7.76 p/Share	3,000 Reduced 2.71%	107,768 Common Stock
May 18 2023	SELL Payment of exercise price or tax liability	$10,964 $6.69 p/Share	1,639 Reduced 1.46%	110,768 Common Stock
May 18 2023	BUY Exercise of conversion of derivative security	-	4,206 Added 3.63%	111,724 Common Stock
Apr 24 2023	SELL Open market or private sale	$30,720 $10.24 p/Share	3,000 Reduced 2.7%	108,201 Common Stock
Mar 24 2023	SELL Open market or private sale	$24,990 $8.33 p/Share	3,000 Reduced 2.63%	111,201 Common Stock
Feb 24 2023	SELL Open market or private sale	$33,150 $11.05 p/Share	3,000 Reduced 2.56%	114,201 Common Stock
Feb 21 2023	SELL Payment of exercise price or tax liability	$7,492 $10.97 p/Share	683 Reduced 0.58%	117,201 Common Stock
Feb 21 2023	BUY Exercise of conversion of derivative security	-	1,752 Added 1.46%	117,884 Common Stock
Jan 24 2023	SELL Open market or private sale	$38,675 $11.05 p/Share	3,500 Reduced 4.4%	76,132 Common Stock
Dec 27 2022	SELL Open market or private sale	$34,195 $9.77 p/Share	3,500 Reduced 4.21%	79,632 Common Stock

Patrik Jeanmonod

CHIEF FINANCIAL OFFICER

Fremont, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CTKB shares.

Notify only if

Value

Insider Trading

Get notified when an Cytek Biosciences, Inc. insider buys or sells CTKB shares.

Notify only if

Operation

Value

Type

News

Receive news related to Cytek Biosciences, Inc.

Track Activities on CTKB

Account